Scheinberg Morton Aaron, Golmia Ricardo Prado, Sallum Adriana Maluf Elias, Pippa Maria Guadalupe Barbosa, Cortada Aline Pinheiros Dos Santos, Silva Telma Gomes da
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Associação de Assistência à Criança Deficiente, São Paulo, SP, Brazil.
Einstein (Sao Paulo). 2015 Oct-Dec;13(4):555-9. doi: 10.1590/S1679-45082015AO3321.
To assess the bone health status of children with cerebral palsy and the therapeutic effect of denosumab in a subgroup of children with cerebral palsy and decreased bone mass.
Children with cerebral palsy were evaluated according to their motor disability score (classification system gross motor functions III to V), bone density and bone turnover markers. Dual X-ray energy absorption was used to measure the lumbar spine, and total body, except the head. Thereafter a group of children with cerebral palsy and osteoporosis was treated with denosumab, a fully human monoclonal antibody. Bone turnover markers were measured before and three months after treatment.
Reduction in bone mineral density was observed, particularly in children with greater impairment evaluated by the motor score. Decreased bone turnover markers were found in a selected group of children three months after exposure to denosumab.
Bone loss was present in children with significant impairment of motor function, as well as decreased serum levels of bone resorption markers with new forms.
评估脑瘫患儿的骨骼健康状况，以及地诺单抗对一组骨量减少的脑瘫患儿的治疗效果。
根据运动残疾评分（粗大运动功能分类系统III至V级）、骨密度和骨转换标志物对脑瘫患儿进行评估。采用双能X线吸收法测量腰椎以及除头部以外的全身骨密度。此后，一组患有脑瘫和骨质疏松症的患儿接受了地诺单抗（一种全人源单克隆抗体）治疗。在治疗前和治疗三个月后测量骨转换标志物。
观察到骨矿物质密度降低，尤其是运动评分评估为损伤更严重的患儿。在接触地诺单抗三个月后的一组选定患儿中发现骨转换标志物降低。
运动功能严重受损的患儿存在骨质流失，同时新型血清骨吸收标志物水平降低。
Zotero 插件